What is indicated for preventing ant chamber involvement in central retinal artery occlusion?

In the context of central retinal artery occlusion (CRAO), preventing anterior chamber involvement is crucial to minimize the risk of complications such as neovascular glaucoma. Acetazolamide, a carbonic anhydrase inhibitor, acts as a diuretic which can help reduce intraocular pressure by decreasing the production of aqueous humor. This reduction in pressure is particularly important in CRAO, where there is the risk of secondary complications related to retinal ischemia.

Utilizing acetazolamide immediately may help alleviate pressure in the eye, which in turn can reduce the risk of damage to the anterior chamber structures and help maintain overall ocular health. The reduction of intraocular pressure is also essential as increased pressure can exacerbate ischemia and lead to further ocular complications.

Other options, while they may have roles in ophthalmic conditions, do not specifically address the need for immediate reduction of intraocular pressure caused by CRAO and its potential complications.